President Donald Trump on Thursday announced agreements with Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) to significantly reduce prices for their GLP-1-based obesity and diabetes drugs.The deals will also expand Medicare and Medicaid coverage for these high-demand treatments beginning in mid-2026.In September, Trump announced the first agreement with a major pharmaceutical company, Pfizer Inc. (NYSE:PFE), to bring American drug prices in line with the lowest paid by other developed nations. ...